Detalhe da pesquisa
1.
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature;
606(7915): 797-803, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35705814
2.
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Nature;
613(7945): E3, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36627494
3.
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Lancet Oncol;
23(10): 1287-1296, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36096156
4.
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.
Cancer;
128(4): 719-726, 2022 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34706060
5.
Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature.
Cancer Invest;
39(1): 9-14, 2021 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33125301
6.
Metaplastic breast cancer: Prognostic and therapeutic considerations.
J Surg Oncol;
123(1): 61-70, 2021 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33047318
7.
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma.
Anticancer Drugs;
31(6): 652-654, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32011367
8.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Breast Cancer Res;
21(1): 153, 2019 12 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31888717
9.
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Lancet Oncol;
19(6): 737-746, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29778737
10.
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
Future Oncol;
13(29): 2629-2644, 2017 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28891712
11.
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.
Lancet Oncol;
21(3): e130, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32135114
12.
Molecular features and clinical outcome of lung malignancies in very young people.
Future Oncol;
11(8): 1211-21, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25832878
13.
Sex as a predictor of response to cancer immunotherapy - Authors' reply.
Lancet Oncol;
19(8): e380-e381, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30102230
14.
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center.
Eur J Cancer;
196: 113423, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37977104
15.
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Clin Cancer Res;
30(6): 1093-1103, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37906083
16.
"Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer."
Breast;
73: 103672, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38244459
17.
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol;
15: 1340979, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38348030
18.
Macrophages and bone metastasis.
J Exp Med;
220(4)2023 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36828392
19.
Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies.
Cancers (Basel);
15(13)2023 Jun 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37444415
20.
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review.
Curr Oncol;
30(3): 3494-3499, 2023 03 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36975478